A black-box warning for antidepressants in children?

New England Journal of Medicine

Volumn 351, Issue 16, 2004, Pages 1595-1598

  Newman, Thomas B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CITALOPRAM; FLUOXETINE; FLUVOXAMINE MALEATE; MIRTAZAPINE; NEFAZODONE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ANXIETY DISORDER; DEPRESSION; DRUG EFFICACY; DRUG LABELING; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HOMICIDE; HUMAN; INSOMNIA; MIGRAINE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SUICIDAL BEHAVIOR; TREATMENT OUTCOME;

ADOLESCENT; ADVERSE DRUG REACTION REPORTING SYSTEMS; ADVISORY COMMITTEES; ANTIDEPRESSIVE AGENTS; CHILD; DATA INTERPRETATION, STATISTICAL; DEPRESSIVE DISORDER; DRUG LABELING; FLUOXETINE; GOVERNMENT REGULATION; HUMANS; META-ANALYSIS; SEROTONIN UPTAKE INHIBITORS; SUICIDE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 5344234529     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMp048279     Document Type: Review

References (2)

1. March J, Silva S, Petrycki S, et al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA 2004;292:807-20.
2. Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 2004;363:1341-5.